Cancer Genetics and Epigenetics, 2025, Vol.13, No.1, 41-49 http://medscipublisher.com/index.php/cge 47 6.3 The innovative prospects of the multi-dimensional treatment system CRISPR technology has demonstrated the potential to transform the clinical practice of breast cancer by constructing a multi-target intervention system. The strategy of synchronously regulating multiple oncogenic network nodes can have a synergistic effect with existing therapies and break through the bottleneck of drug resistance. This multi-pathway combined intervention significantly reduced the adaptive escape probability of tumors (Chen and Zhang, 2018; Liu et al., 2019; Ghaemi et al., 2020). The precise editing scheme based on the genetic characteristics of tumors can maximize the protection of normal tissues while improving the therapeutic effect. With the development of technology, the deep integration of CRISPR with immune regulation and targeted delivery systems will promote the treatment of breast cancer to a new stage of precision and systematization (Sharma et al., 2020; Allemailem et al., 2022). 7 Concluding Remarks CRISPR, as a novel gene editing technology, plays an important role in regulating the key targets of HER2-positive breast cancer. Experiments have confirmed that precise editing of the HER2 gene can not only prevent the excessive growth of cancer cells, but also inhibit harmful mutations and interfere with the core signal transmission of tumors. This technology, by constructing an experimental model of HER2 inactivation, can deeply analyze the core mechanism of tumor growth and provide theoretical support for drug development. These findings demonstrate the crucial role of CRISPR in improving the treatment regimens for HER2-positive breast cancer. Although the prospects are promising, CRISPR still faces many technical challenges in actual clinical applications. At present, the requirements for editing accuracy are extremely high, and the off-target rate needs to be further reduced. Meanwhile, the efficiency of gene delivery tools still needs to be improved. The targeting capabilities of existing viral vectors and non-viral systems are still insufficient, and it is necessary to improve them through bioengineering means. In addition, the full-process supervision and verification system from laboratory achievements to clinical applications urgently needs to be improved to ensure the stability and safety of treatment. The application of CRISPR technology in clinical practice requires the establishment of an interdisciplinary cooperation platform. Combining resources from biology, medicine and engineering, it can collaboratively solve the problems of drug delivery and the challenges of tumor heterogeneity. This also involves detailed research on the characteristics of the tumor microenvironment, the development of precise drug delivery methods, and the promotion of standardized clinical trials. Only through multidisciplinary collaboration can the advantages of CRISPR technology be fully leveraged to provide more precise treatment plans for patients with HER2-positive breast cancer. Acknowledgments We extend our sincere thanks to two anonymous peer reviewers for their feedback on the initial draft of this study, whose conscientious evaluations and constructive suggestions have contributed to the improvement of our manuscript. Conflict of Interest Disclosure The authors affirm that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. Reference Allemailem K.S., Almatroodi S.A., Almatroudi A., Alrumaihi F., Abdulmonem A., Al-Megrin W.A., Aljamaan A.N., Rahmani A.H., and Khan A.A., 2023, Recent advances in genome-editing technology with CRISPR/Cas9 variants and stimuli-responsive targeting approaches within tumor cells: a future perspective of cancer management, International Journal of Molecular Sciences, 24(8): 7052. https://doi.org/10.3390/ijms24087052 Allemailem K., Alsahli M., Almatroudi A., Alrumaihi F., Alkhaleefah F., Rahmani A., and Khan A., 2022, Current updates of CRISPR/Cas9‐mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management, Cancer Communications, 42(12): 1257-1287. https://doi.org/10.1002/cac2.12366
RkJQdWJsaXNoZXIy MjQ4ODYzNA==